Renal cell carcinoma echocardiography or ultrasound

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Renal cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal cell carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal cell carcinoma echocardiography or ultrasound On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal cell carcinoma echocardiography or ultrasound

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal cell carcinoma echocardiography or ultrasound

CDC on Renal cell carcinoma echocardiography or ultrasound

Renal cell carcinoma echocardiography or ultrasound in the news

Blogs on Renal cell carcinoma echocardiography or ultrasound

Directions to Hospitals Treating Renal cell carcinoma

Risk calculators and risk factors for Renal cell carcinoma echocardiography or ultrasound

Ultrasound

Ultrasound (US) may be helpful when CT scan results are equivocal. It is noteworthy to mention that not all renal cell carcinomas are detectable on ultrasound.

Use of US in Renal Cell Carcinoma[1]
Patient Profile Use of US Evidence Strength
Low Risk Patient (pT1, N0, Nx) US (or CT or MRI) may be performed in patients following radical nephrectomy if initial post-op baseline image is negative C
Moderate to High Risk Patients (pT2-4N0 Nx or any stage N+) Imaging, including US, may be used every 6 months (after a baseline chest and abdominal CT or MRI within 3-6 months following surgery) for at least 3 years and annually thereafter to 5 years. Site specific imaging is warranted by clinical symptoms suggestive of recurrence or metastatic spread. Imaging (US, CXR, CT, or MRI) beyond 5 years may be performed at the discretion of the clinician C

References

  1. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH; et al. (2013). "Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline". J Urol. 190 (2): 407–16. doi:10.1016/j.juro.2013.04.121. PMID 23665399.